SCHEMBL2116719

SCHEMBL2116719

COc1cc(S(=O)(=O)Nc2cc(-n3cccc3)ccc2C)ncn1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 3/20 0.39
MAPT P10636 4/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
ALDH1A1 P00352 3/20 0.38
TDP1 Q9NUW8 2/20 0.38
POLB P06746 1/20 0.38
HSD17B10 Q99714 1/20 0.38
KDM4E B2RXH2 1/20 0.38
PKM P14618 1/20 0.38
BLM P54132 1/20 0.38
CYP2C19 P33261 1/20 0.37
CYP2C9 P11712 2/20 0.35
TSHR P16473 2/20 0.35
CCNT1 O60563 1/20 0.35
CDK9 P50750 1/20 0.35
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2119955 0.82 KMT2A (0.43) P2RX7MAPTMEN1KMT2AALDH1A1
SCHEMBL2117300 0.80 MAPT (0.46) P2RX7MAPTMEN1KMT2AALDH1A1
SCHEMBL2119327 0.80 MEN1 (0.46) MAPTMEN1KMT2AALDH1A1TDP1
SCHEMBL2117726 0.79 P2RX7 (0.40) P2RX7MAPTMEN1KMT2AALDH1A1
SCHEMBL2117318 0.78 MEN1 (0.43) P2RX7MAPTMEN1KMT2AALDH1A1
SCHEMBL2122490 0.75 SLC40A1 (0.49) P2RX7MAPTMEN1KMT2APOLB
SCHEMBL2118328 0.75 TRIM24 (0.45) MAPTALDH1A1POLB
SCHEMBL2121927 0.75 KDM4E (0.45) MAPTMEN1KMT2AALDH1A1POLB
SCHEMBL2121515 0.74 GHSR (0.43) P2RX7MAPTPOLBCYP2C19
SCHEMBL2119213 0.74 ACLY (0.49)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed
EP-2382190-A1 TOLUIDINE SULFONAMIDES AND THEIR USE AS-INHIBITORS European Molecular Biology Laboratory (EMBL) (DE) 2011-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1A, HIF1AN, EGLN3 P2RX7 1426/4885MAPT 4747/4885MEN1 3143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.